While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...

Therapeutic drug monitoring (TDM) of Busulfan is essential for management of Bone Marrow Transplant (BMT) patients, by optimizing dose, supporting compliance, and minimizing toxicity. Busulfan is a ...

Either hydroxyurea or busulfan as single agents can provide hematologic control in the majority of patients (> 75%) with chronic phase CML. [32] These hematologic "remissions" are characterized by ...

a “conditioning” course of a highly toxic chemotherapy called busulfan required to eliminate diseased cells from the bone marrow and make room for the genetically modified cells. Gene editing ...

Umbilical cord blood transplant has been successfully performed for CML patients in accelerated phase or blastic transformation. [87,88,89] The utility of cord blood transplants for adult ...

In the trial, patients underwent a myeloablative conditioning regimen with busulfan before receiving the edited cells. The ...

The research team used three anticancer drugs: Busulfan, Fludarabine, and Etoposide to perform customized anticancer drug ...

Shares of Editas Medicine EDIT gained 4.2% on Monday after the company announced updated safety and efficacy data from the ...

Safety Profile Consistent with Busulfan and Autologous Hematopoietic Stem Cell Transplantation. In November, the company said that one patient died due to respiratory failure likely related to ...

Beam Therapeutics unveiled BEAM-101 trial data at ASH, showing improved outcomes in sickle cell patients and promising ...

Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K.

Nearly all the patients with severe SCD treated with the gene-editing therapy reni-cel remained free of VOEs for up to two ...